Avosentan for overt diabetic nephropathy. - Wikidata - awgldk - TriplyDB

Avosentan for overt diabetic nephropathy.

Avosentan for overt diabetic nephropathy.

http://www.wikidata.org/entity/Q33702404

about

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease Endothelin Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade Endothelin Blockade in Diabetic Kidney Disease Present and future in the treatment of diabetic kidney disease Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Diabetic kidney disease: from physiology to therapeutics Endothelin receptors and their antagonists Renal autoregulation in health and disease Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial Diabetic nephropathy - Epidemiology in Asia and the current state of treatment Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists.The paradox of bardoxolone methyl: a call for every witness on the stand?Slowing progression of chronic kidney disease Treatment of diabetic kidney disease: current and future targets.Advances in the pathophysiology of pre-eclampsia and related podocyte injury.Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.Diabetic nephropathy - complications and treatment.Emerging drugs for chronic kidney disease.Endothelin and endothelin antagonists in chronic kidney disease.Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness.Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.Therapeutic targets for treating fibrotic kidney diseases Glomerular endothelial cell injury and cross talk in diabetic kidney disease Flow regulation of endothelin-1 production in the inner medullary collecting duct Hypertension in Cardiovascular and Kidney Disease.Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.Endothelin and the podocyte Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade.Epigenetics in diabetic kidney disease.Renal hyperfiltration related to diabetes mellitus and obesity in human disease.Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View Gq signaling causes glomerular injury by activating TRPC6.

P2860

Q26752292-06CBD589-D0E3-4A96-8591-DDF035990DC5 Q26767156-0C73A3DB-7D32-462B-997B-E86C04D47E3F Q26799443-FC6ED0C8-E826-4DF5-8931-4F3B78C0C963 Q26799476-CCAB54D3-3489-42F6-847C-8BBF9C0728CD Q26864133-B64FD69E-FBC3-469B-B66C-C0A674B9F67A Q27007027-384AA7B3-3F16-4E0C-BCE9-77F03C0F1CD2 Q27021392-A7E61B95-6E8C-4F46-8544-005FC7C8D2FE Q27023208-206D9811-A8FE-44E0-A54D-88016BB0A177 Q28082365-E36CDF5E-38A1-47BD-81C5-A428D8EF67C9 Q28086840-9C1F7D3E-F44E-442C-90C7-D9C4A82C0484 Q28237978-755531BC-2C50-4516-A89F-639A387DAEAB Q28546969-3CB1F046-F0A9-4E0F-A97A-F168119D3215 Q28742785-4C8AC531-D06F-4F75-BF72-83D63205C866 Q33167828-F1A8B504-2730-429C-97EA-0BA11AAA8E28 Q33358784-50AF847F-E8A4-46A5-A4CA-9F4803E8B84A Q33873241-FD8A3647-F976-4B3D-B98C-074B496599C0 Q33907249-47FF49FA-A660-4DDD-AB93-E0DF40F1BD73 Q33983807-30B3EA46-9BE8-4A8A-8EE9-FC43E80A2871 Q34360718-7F9343DA-CCD9-4B9C-B6B5-EFA1DB5609A4 Q34383685-5A41CDF0-8AE2-43A3-9ED9-47FD96971749 Q34387952-E0E05559-981B-46B1-971A-065A9DFBC81B Q34420383-E37535C5-FB54-4259-8637-680E9EC180CD Q34437692-97B14A37-0BCB-45F9-99C9-6C00DDA91D5E Q34502911-46A4A912-AECF-4436-AB32-8F33817A353C Q34604473-5AF1C5D2-9530-4014-BE9F-1E68CE065ED5 Q34632600-35681B5F-C230-4A8A-8625-348BFFAA41CB Q34726905-4FDB3964-F457-4757-A8BA-F0076D5DD46B Q34787799-B0D65783-835B-4C09-99DE-A65F1BC63656 Q35050553-07798F8A-393A-4951-BD75-C9D338116307 Q35079607-14B2A5CB-E14E-430D-831F-76733E72D82D Q35086477-7900DD24-9C0B-43BE-A7EB-635CDBE22AD4 Q35178609-90A79B71-239C-4127-B5E1-FB77218DED2C Q35203404-D4AA1E6B-EEFE-46B0-A731-B2E0379552F9 Q35207830-0D1749FF-DA06-4EEE-9B62-64D6BA026B39 Q35452282-BC6C96F2-7C7C-464A-A5B9-2A69E8FE6ADC Q35549144-71735BF1-D62E-4BA0-BE80-EF452339EA3D Q35647853-F1254F99-7077-49EB-B799-E84EE14C8ACD Q35673442-DF81A1C3-7C5B-4ECC-A70C-73708E2C6A25 Q35682234-19271044-7409-4A7D-A2F7-0279E5C2C13A Q35719874-861A63D8-F682-4EAE-9864-DC27430340FF

P2860

Avosentan for overt diabetic nephropathy.

http://www.wikidata.org/entity/Q33702404

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Avosentan for overt diabetic nephropathy.

@ast

Avosentan for overt diabetic nephropathy.

@en

type

label

Avosentan for overt diabetic nephropathy.

@ast

Avosentan for overt diabetic nephropathy.

@en

prefLabel

Avosentan for overt diabetic nephropathy.

@ast

Avosentan for overt diabetic nephropathy.

@en

P1433

Q33702404-A0249947-EA9C-4768-BBB9-386719B19EF0

P1476

Q33702404-0A25BDC9-76D5-46DD-AD2B-83C058502E7E

P2093

Q33702404-1FA5C575-F128-4201-BCAF-5300DC8F3F63

Q33702404-3E237B08-93F7-4B00-8A7B-FB3302DCF691

Q33702404-55238C74-B2C9-4B8A-A569-F40E4CA55AE5

Q33702404-6A8ECF5E-365B-41F6-9F8B-F4A21B93C8B0

Q33702404-8969B51B-C4E0-4DC7-BB84-8312D3EDA7E1

Q33702404-C452998C-8BA9-4A63-AAC0-E0678397AD56

Q33702404-C54856E0-138D-4139-A8DD-E186EB5B519B

P2860

Q33702404-048711A4-ACAA-4B40-A8BF-1F922BE86AE3

Q33702404-148C8C19-287B-4BB3-BF43-3C205080BD66

Q33702404-28D5F420-2AEB-46A2-A6A0-B4944CA3B134

Q33702404-37FBED43-8F3C-48C7-BBE5-64449612BD1F

Q33702404-3F31F9FB-CF5D-4B9A-94E7-F9D68FDAE741

Q33702404-5D68E805-765B-4ACC-BB59-F4C6B49CC4B2

Q33702404-5E65EE83-FEB5-4C9D-BF3C-1B2F155D4BB1

Q33702404-63821697-8DCC-45A5-8391-513168BBAEFA

Q33702404-7FF33D5F-63DD-4AE7-B4C7-FEC820D5D6B6

Q33702404-90AB1B38-73CC-47F4-A9EF-EBC97F6B3CCA

P304

Q33702404-3B13F0AA-E4F5-4E96-A119-20BF38CB9998

P31

Q33702404-45C0C387-FD5F-4749-8690-A8DDEF8C52A1

P356

Q33702404-51F1875A-D7B1-4207-9FBD-91B30CF10B4D

P433

Q33702404-8D69068A-7CCA-4051-A5C0-CB14A14ACE08

P478

Q33702404-53C6C00E-433E-4F6E-A845-75FFAAD8EA00

P50

Q33702404-939E40A1-077F-4EA8-8FFD-55029B5AF8F3

P577

Q33702404-9E71FDF2-8762-445B-828C-C5782D03FDC3

P698

Q33702404-48CE829A-8084-4062-8A87-D5060606CA23

P932

Q33702404-9A773733-4D75-4EF4-9FD4-7A15ADB1C824

P356

P1433

Journal of the American Society of Nephrology

P1476

Avosentan for overt diabetic nephropathy.

@en

P2093

ASCEND Study Group

http://www.w3.org/2001/XMLSchema#string

Damian Green

http://www.w3.org/2001/XMLSchema#string

Giancarlo Viberti

http://www.w3.org/2001/XMLSchema#string

Johannes F E Mann

http://www.w3.org/2001/XMLSchema#string

Kenneth Jamerson

http://www.w3.org/2001/XMLSchema#string

Susan J Kuranoff

http://www.w3.org/2001/XMLSchema#string

Thomas Littke

http://www.w3.org/2001/XMLSchema#string

P2860

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Endothelin in cardiovascular control: the role of endothelin antagonists.

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.

Assessing kidney function--measured and estimated glomerular filtration rate.

Endothelin receptor antagonists in heart failure: current status and future directions.

Clinical trials of endothelin antagonists in heart failure: a question of dose?

Antihypertensive therapy in the presence of proteinuria.

P304

527-535

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2009060593

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Luis Miguel Ruilope

P577

2010-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20167702

http://www.w3.org/2001/XMLSchema#string

P932

2831858

http://www.w3.org/2001/XMLSchema#string